Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,763 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D, Pham NA, Tong J, Sakashita S, Allo G, Kim L, Yanagawa N, Raghavan V, Wei Y, To C, Trinh QM, Starmans MH, Chan-Seng-Yue MA, Chadwick D, Li L, Zhu CQ, Liu N, Li M, Lee S, Ignatchenko V, Strumpf D, Taylor P, Moghal N, Liu G, Boutros PC, Kislinger T, Pintilie M, Jurisica I, Shepherd FA, McPherson JD, Muthuswamy L, Moran MF, Tsao MS. Wang D, et al. Among authors: kim l. Int J Cancer. 2017 Feb 1;140(3):662-673. doi: 10.1002/ijc.30472. Epub 2016 Nov 7. Int J Cancer. 2017. PMID: 27750381 Free article.
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS. Stewart EL, et al. Among authors: kim l. J Clin Oncol. 2015 Aug 1;33(22):2472-80. doi: 10.1200/JCO.2014.60.1492. Epub 2015 Jun 29. J Clin Oncol. 2015. PMID: 26124487
Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
Martin P, Stewart E, Pham NA, Mascaux C, Panchal D, Li M, Kim L, Sakashita S, Wang D, Sykes J, Friess T, Shepherd FA, Liu G, Tsao MS. Martin P, et al. Among authors: kim l. Clin Lung Cancer. 2016 Sep;17(5):375-383.e2. doi: 10.1016/j.cllc.2016.01.002. Epub 2016 Jan 22. Clin Lung Cancer. 2016. PMID: 26926157
A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.
Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, de Perrot M, Shepherd FA, Liu G, Tsao MS, Leighl NB. Sacher AG, et al. Among authors: kim l. Oncotarget. 2016 May 3;7(18):25632-9. doi: 10.18632/oncotarget.8350. Oncotarget. 2016. PMID: 27028852 Free PMC article. Clinical Trial.
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.
Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA. Leighl NB, et al. Among authors: kim l. Oncotarget. 2017 Jun 28;8(41):69651-69662. doi: 10.18632/oncotarget.18753. eCollection 2017 Sep 19. Oncotarget. 2017. PMID: 29050231 Free PMC article.
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients.
Kim L, Saieg M, Di Maio M, Gallo C, Butts C, Ciardiello F, Feld R, Cheng D, Gebbia V, Burgio MA, Alam Y, Signoriello S, Rossi A, Leighl N, Maione P, Morabito A, Liu G, Tsao MS, Perrone F, Gridelli C. Kim L, et al. Oncotarget. 2017 Feb 25;8(34):57528-57536. doi: 10.18632/oncotarget.15725. eCollection 2017 Aug 22. Oncotarget. 2017. PMID: 28915692 Free PMC article.
2,763 results